Powering the Immune System to Transform Lives

Elliott Sigal photoElliott Sigal, M.D., Ph.D.


Elliott Sigal, M.D, Ph.D., has served as a member of our Board since July 2020. 

Dr. Sigal currently serves as a senior advisor to select biotechnology companies. He is co-chair of the Scientific Advisory Board of Amgen and is a member of the Sean Parker Institute for Cancer Immunotherapy Scientific Steering Committee. He is a member of the Board of Directors for the public biotechnology companies Alnylam Pharmaceuticals, Adaptimmune Therapeutics and Surface Oncology, as well as the private companies Tessera Therapeutics and Affinia Therapeutics. 

He previously served as a director of Spark Therapeutics, Mead Johnson Nutrition and Bristol-Myers Squibb (BMS). Dr. Sigal is a former Executive Vice President and Director of BMS, and served as Chief Scientific Officer and President of R&D from 2004 until 2013. Under his leadership, 14 new medicines came to market.

Positions prior to BMS include a faculty appointment at University of California, San Francisco (UCSF), senior executive roles at Syntex/Roche and CEO of the genomics firm, Mercator Genetics.

Dr. Sigal holds B.S., M.S. and Ph.D. degrees in industrial engineering from Purdue University and an M.D. from the University of Chicago.